

AngioDynamics Reports 3.15% CAGR Growth Through 2032 Revenue to Reach \$1.64 Billion

AngioDynamics

Inc.



“AngioDynamics is a leader in the medical device industry, and its strong performance is a testament to the company's commitment to innovation and patient care. We expect continued growth through 2032, with revenue reaching \$1.64 billion.”

Analytica Global

TOKYO, JAPAN, December 20, 2024 /EINPresswire.com/ --

AngioDynamics, a leading medical device manufacturer, has reported a 3.15% CAGR growth through 2032, with revenue reaching \$1.64 billion. The company's strong performance is a testament to its commitment to innovation and patient care. AngioDynamics is a leader in the medical device industry, and its strong performance is a testament to the company's commitment to innovation and patient care. We expect continued growth through 2032, with revenue reaching \$1.64 billion.

AngioDynamics is a leading medical device manufacturer, and its strong performance is a testament to the company's commitment to innovation and patient care.

AngioDynamics (NYSE:AD) is a leading medical device manufacturer, and its strong performance is a testament to the company's commitment to innovation and patient care. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR.

AngioDynamics reported 2022 revenue of \$1.2 billion, 2023 revenue of \$1.25 billion, and 2032 revenue of \$1.64 billion, representing a 3.15% CAGR.

Request a sample (PDF) @:

<https://www.analytica.global/request-sample/54>

AngioDynamics is a leading medical device manufacturer, and its strong performance is a testament to the company's commitment to innovation and patient care.

AngioDynamics is a leading medical device manufacturer, and its strong performance is a testament to the company's commitment to innovation and patient care. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR. The company's revenue is expected to reach \$1.64 billion by 2032, with a 3.15% CAGR.

AngioDynamics is a leading medical device manufacturer, and its strong performance is a testament to the company's commitment to innovation and patient care.

AngioDynamics

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.